Margalit E. Rosenkranz

Long-term safety of canakinumab in patients with systemic juvenile idiopathic arthritis: 5-year results from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry

Alis Burciu, Amita Bansal, Anne C. Dennos, Deepak Narayanswamy et autres

BACKGROUND: Systemic juvenile idiopathic arthritis (SJIA) is a severe form of juvenile idiopathic arthritis characterized by fever, rash, chronic arthritis, and systemic inflammation. The introduction of biologics has improved the treatment options for SJIA. Canakinumab selectively inhibits interleukin-1β and is approved for …

ch, us, in (code pays fourni par la source)

Implementation study of the CARRA Uveitis Consensus Treatment Plans: feasibility for clinical practice and applicability for research

Margaret H. Chang, Fatima A. Barbar-Smiley, Shoghik Akoghlanian, Joanne Drew et autres

BACKGROUND: Chronic anterior uveitis (CAU) carries a significant risk for eye complications and vision loss. The Childhood Arthritis and Rheumatology Research Alliance (CARRA) introduced consensus treatment plans (CTPs) to standardize treatment for CAU and facilitate future comparative effectiveness studies. Two CTPs were …

us (code pays fourni par la source)

Plasma cell-free RNA signatures of inflammatory syndromes in children

Conor Loy, Venice Servellita, Alicia Sotomayor-González, Andrew Bliss et autres

Inflammatory syndromes, including those caused by infection, are a major cause of hospital admissions among children and are often misdiagnosed because of a lack of advanced molecular diagnostic tools. In this study, we explored the utility of circulating cell-free RNA (cfRNA) in …

us (code pays fourni par la source)

Molecular Regulation of Bone Turnover in Juvenile Idiopathic Arthritis: Animal Models, Cellular Features and TNFα

Harry C. Blair, Jonathan Soboloff, Irina L. Tourkova, Jamie L. McCall et autres

We review the abnormal bone turnover that is the basis of idiopathic inflammatory or rheumatoid arthritis and bone loss, with emphasis on Tumor Necrosis Factor-alpha (TNFα)-related mechanisms. We review selected data on idiopathic arthritis in juvenile human disease, and discuss mouse models …

us, it (code pays fourni par la source)

Safety and effectiveness of abatacept in juvenile idiopathic arthritis: results from the PRINTO/PRCSG registry

Daniel J. Lovell, Nikolay Tzaribachev, Michael Henrickson, Gabriele Simonini et autres

OBJECTIVE: The aim of this study was to report the interim 5-year safety and effectiveness of abatacept in patients with JIA in the PRINTO/PRCSG registry. METHODS: The Abatacept JIA Registry (NCT01357668) is an ongoing observational study of children with JIA receiving abatacept; …

us, de, it, ru, lv, gr, ca, fr (code pays fourni par la source)

Relentless placoid chorioretinitis: A review of four cases in pediatric and young adult patients with a discussion of therapeutic strategies

Haniah A. Zaheer, Jamie L. Odden, Meghal Gagrani, Fatma Zaguia et autres

Introduction: Relentless placoid chorioretinitis (RPC) is a rare, bilateral disease of the retinal pigment epithelium. The clinical course is prolonged and relapsing. No standard treatment has been established to date. The purpose of this case series is to report four cases of …

us, ca, fr (code pays fourni par la source)

First-line options for systemic juvenile idiopathic arthritis treatment: an observational study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans

Timothy Beukelman, GEORGE A. TOMLINSON, Peter Andrija Nigrovic, Anne C. Dennos et autres

BACKGROUND: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) developed consensus treatment plans (CTPs) to compare treatment initiation strategies for systemic juvenile idiopathic arthritis (sJIA). First-line options for sJIA treatment (FROST) was a prospective observational study to assess CTP outcomes using the …

us, ca (code pays fourni par la source)

Intraarticular steroids as DMARD-sparing agents for juvenile idiopathic arthritis flares: Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry

Timothy Hahn, Carrie B. Daymont, Timothy Beukelman, Brandt P. Groh et autres

BACKGROUND: Children with juvenile idiopathic arthritis (JIA) who achieve a drug free remission often experience a flare of their disease requiring either intraarticular steroids (IAS) or systemic treatment with disease modifying anti-rheumatic drugs (DMARDs). IAS offer an opportunity to recapture disease control …

us (code pays fourni par la source)

Baseline characteristics of children with juvenile dermatomyositis enrolled in the first year of the new Childhood Arthritis and Rheumatology Research Alliance registry

Jessica A Neely, Kaveh Ardalan, Adam M. Huber, Susan Kim et autres

BACKGROUND: To report baseline characteristics, patient reported outcomes and treatment of children with Juvenile Dermatomyositis (JDM) in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. METHODS: Children newly diagnosed with JDM were enrolled in the CARRA Registry from 41 pediatric rheumatology …

us, ca (code pays fourni par la source)

Trajectories of disease activity in patients with JIA in the Childhood Arthritis and Rheumatology Research Alliance Registry

Natalie Jane Shiff, Peter Shrader, Colleen K. Correll, Anne C. Dennos et autres

OBJECTIVE: To describe 2-year trajectories of the clinical Juvenile Arthritis Disease Activity Score, 10 joints (cJADAS10) and associated baseline characteristics in patients with JIA. METHODS: JIA patients in the Childhood Arthritis and Rheumatology Research Alliance Registry enrolled within 3 months of diagnosis …

ca, us (code pays fourni par la source)

Review of spinal involvement in chronic recurrent multifocal osteomyelitis (CRMO): What radiologists need to know about CRMO and its imitators

Amisha J. Shah, Margalit E. Rosenkranz, Mahesh M. Thapa

us (code pays fourni par la source)

Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial

Jane C. Burns, Samantha C. Roberts, Adriana H. Tremoulet, Feng He et autres

BACKGROUND: Although intravenous immunoglobulin (IVIG) is effective therapy for Kawasaki disease, 10-20% of patients have recrudescent fever as a sign of persistent inflammation and require additional treatment. We aimed to compare infliximab with a second infusion of IVIG for treatment of resistant …

us (code pays fourni par la source)